Summary

  • MiniMed reported first-quarter revenue of $843 million and organic revenue of $829 million, up 15.8% from an adjusted prior-year base of $716 million.
  • Medtronic reported the same $843 million of Diabetes revenue and the same $829 million organic numerator, but called growth 14.9% against a $721 million prior-year base.
  • MiniMed starts from $723 million of prior reported revenue and removes a $7 million Italian payback-accrual benefit; Medtronic's reported comparator is already $2 million lower before that adjustment.
  • Both issuers warn that the comparison crosses a carve-out-to-standalone boundary, and the current quarter also contains an extra fiscal week.
  • MiniMed is publicly traded, but Medtronic still owned about 90.03% after the IPO and had not made a final decision on the remaining split-off.

The most useful line in MiniMed's first public quarterly scorecard is not its strongest growth rate. It is the line that shows why a growth rate needs an owner.

MiniMed's 1 September Form 8-K attaches a quarter of $843 million in net sales. The detailed earnings exhibit removes $14 million of favourable currency impact, leaving $829 million of current organic revenue. It compares that with $716 million and reports 15.8% organic growth.

Medtronic's separate 8-K also reports $843 million for Diabetes. Its earnings exhibit makes the same $14 million currency adjustment and reaches the same $829 million current organic numerator. Its comparison base is $721 million, and its published organic growth is 14.9%.

The numerator has not moved. The history has.

Three prior-year numbers sit behind two rates

MiniMed's reported table begins with $723 million for the quarter ended 25 July 2025. Against $843 million, that produces 16.6% reported growth after rounding. MiniMed then removes a $7 million prior-year benefit related to adjustments to its Italian payback accrual, reducing the organic comparator to $716 million. Dividing $829 million by that base produces 15.8%.

Medtronic begins from $721 million for the same Diabetes line. Against $843 million, that produces 16.9% reported growth. It leaves the organic comparator at $721 million; $829 million over that base is close to 15.0% using the rounded table, while Medtronic publishes 14.9% from its unrounded records.

The Italian item is therefore important, but it is not the whole bridge. The issuers already differ by $2 million at reported revenue. MiniMed then makes a $7 million adjustment that Medtronic's table does not show. The resulting organic denominators differ by $5 million.

This is not evidence that one company invented sales. Both disclose the same current $843 million and the same currency-adjusted $829 million. It is evidence that “organic” is a governed comparison, not an observed cash balance.

The accounting boundary is disclosed, not hidden

Medtronic places an unusually direct footnote under its Diabetes table: the results may not correspond to MiniMed's financial-statement information because MiniMed was prepared on a carve-out basis through its initial public offering and on a standalone basis afterward.

MiniMed's February registration statement explains what that sentence carries. The historical combined accounts came from Medtronic's records. They included allocations for finance, supply chain, human resources, information technology, insurance, employee benefits and other shared services. The filing says those allocations may not reflect the expenses MiniMed would have incurred as a standalone public company.

The current quarter ended after the IPO. The prior quarter did not. A comparison can be arithmetically correct while still joining two operating and accounting states.

That does not make year-on-year analysis useless. It changes the minimum receipt. A reader needs the reported revenue bridge, each non-GAAP adjustment, the week count and the point at which allocated parent costs became contractual transition costs or independent expenses.

A 14-week quarter adds a third clock

Fiscal 2027 has 53 weeks, and the extra week fell in the first quarter. MiniMed estimates that it added an approximate 4% to 6% benefit and says growth remained in the low double digits without it. It does not publish an exact 13-week revenue figure.

The full-year guide of about 10.5% organic growth includes an approximate 1.0% to 1.5% extra-week benefit. Medtronic separately estimates that the extra week added about $570 million to group organic revenue growth, but it does not allocate that amount to Diabetes.

Those disclosures stop two tempting shortcuts. The 15.8% rate should not be read as a pure same-week demand rate. Nor can Medtronic's group estimate be distributed mechanically across Diabetes, cardiovascular, neuroscience and surgical products.

MiniMed gives positive operating evidence that is not dependent on the percentage label: US revenue grew to $240 million, international revenue to $603 million, new pumps sold reached about 34,000 and the continuous-glucose-monitor attachment rate reached 69%. Those are useful signals, but even they still contain the longer quarter.

A listing did not finish the separation

MiniMed's IPO closing filing records 28 million shares sold at $20 each. Net proceeds were about $538 million. MiniMed retained $309 million, bringing cash on hand to about $350 million, and used the excess to repay intercompany debt to Medtronic.

The same filing says Medtronic owned approximately 90.03% after the offering. MiniMed had a public price and minority shareholders, but it remained a controlled company.

On 1 September, Medtronic still described the final separation as a series of possible capital-market transactions. A split-off was the preferred route, but no final decision had been made. The registration statement is even clearer: Medtronic had no obligation to complete the later divestment by a specified date or at all.

That ownership boundary matters to the measurement boundary. Medtronic still consolidates the business and presents a Diabetes line. MiniMed presents itself to public shareholders on a standalone basis. Until ownership, services and reporting history are fully separated, the two views will coexist.

Growth now has to convert through a new cost base

MiniMed reported $465 million of gross profit, $115 million of research and development expense, $312 million of selling, general and administrative expense, $36 million of other operating expense and $5 million of operating income. Net income rounded to zero.

The company reaffirmed an adjusted EBITDA margin target of about 16% for the year. That target cannot be evaluated only by choosing the larger organic-growth rate. The registration statement records transition services, intellectual-property licences, trademark arrangements, a property-and-services agreement in Puerto Rico, and transitional manufacturing and supply obligations. Some parent allocations will become contract charges; some services must eventually be replaced.

Medtronic's 2026 annual filing confirms both the continuing 90.03% holding at the IPO close and the transition-services framework. The next durable margin comparison needs to distinguish volume leverage from an extra week, separation cost, inherited allocation, transition charge and replacement cost.

The two organic-growth rates are therefore not a puzzle to solve with an average. They are a map of an unfinished handoff. MiniMed owns one definition. Medtronic owns another. Investors need both definitions labelled until a stable standalone history replaces the bridge.

Sources